Evaluate the Safety and Clinical Activity of HH2853
A phase 1/2 trial of HH2853 Tablets in non-Hodgkin lymphoma, epithelioid sarcoma and peripheral T-cell lymphomas, run by Haihe Biopharma Co., Ltd., now recruiting.
Overview
Evaluate the Safety and Clinical Activity of HH2853 is a phase 1/2 interventional study registered as NCT04390737 by Haihe Biopharma Co., Ltd., with 254 participants planned, started 2020-09-08 and due to reach its primary completion in 2027-12-31. Interventions recorded: HH2853 Tablets.
Similar pages
not linked directly; found by shared links- TrialStudy to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
Shares Haihe Biopharma, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialValemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialAdaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialAssessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
Shares Haihe Biopharma and the tag pipeline.
- TrialA Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.
Shares Epithelioid sarcoma and the tag pipeline.
- TrialA Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialA Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma
Shares Haihe Biopharma and the tag pipeline.